Novel immunotargets in multiple myeloma: biological relevance
and therapeutic potential

J 2025

Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential

KOTULOVÁ, Jana; Klára BAĎUROVÁ; Zuzana CHYRA; Sabina ŠEVČÍKOVÁ; Nikola GARBOVÁ et al.

Základní údaje

Originální název

Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential

Autoři

KOTULOVÁ, Jana; Klára BAĎUROVÁ; Zuzana CHYRA; Sabina ŠEVČÍKOVÁ; Nikola GARBOVÁ; Tomáš JELÍNEK; Roman HÁJEK a Matouš HRDINKA

Vydání

Biomarker Research, LONDON, BMC, 2025, 2050-7771

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.500 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; Aberrant plasma cells; Hematooncology; Immunotarget; Immunotherapy; Surface proteome; Surfaceomics; Biomarker discovery

Štítky

14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 8. 2025 09:08, Mgr. Tereza Miškechová

Anotace

V originále

Multiple myeloma is a hematologic malignancy characterized by complex genetic and microenvironmental factors that drive disease progression and resistance to treatment. Despite advancements in therapies targeting established antigens, such as BCMA, CD38, SLAMF7, and GPRC5D, specific challenges persist, including antigen escape, treatment resistance, and off-tumor toxicity, highlighting the urgent need for novel therapeutic modalities. Recent advances in surface proteomics and integrative omics technologies have enabled the discovery of new surface antigens with the potential to address the challenges. By targeting antigens with higher tumor specificity and lower expression in healthy tissues, emerging immunotargets offer new avenues to minimize off-tumor toxicity and reduce the risk of relapse due to antigen loss or immune evasion. This review provides an overview of emerging immunotargets, summarizing their biological functions, roles in disease pathogenesis and immune evasion, and potential for therapeutic interventions. We focused on fifteen emerging targets currently in early clinical development or the preclinical phase, highlighting LILRB4, SEMA4A, ITGB7, CCR1, and CD70 as the most promising. These immunotargets demonstrate significant potential for next-generation immunotherapies, including antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Preclinical or early clinical studies show favorable safety profiles, high tumor specificity, and mechanisms to overcome immune resistance, collectively suggesting the potential for improved patient outcomes and reduced adverse effects. By presenting a comprehensive summary of these advances, this review underscores the translational potential of emerging immunotargets and provides insights to guide the development of innovative therapeutic approaches to improve outcomes for multiple myeloma patients.

Návaznosti

EH22_008/0004644, projekt VaV

Název: Záchrana životů prostřednictvím výzkumu v oblasti včasné detekce a prevence rakoviny: Molekulární, genomické a sociální faktory

Citovat

KOTULOVÁ, Jana; Klára BAĎUROVÁ; Zuzana CHYRA; Sabina ŠEVČÍKOVÁ; Nikola GARBOVÁ; Tomáš JELÍNEK; Roman HÁJEK a Matouš HRDINKA. Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. Biomarker Research. LONDON: BMC, 2025, roč. 13, July 2025, s. 1-26. ISSN 2050-7771. Dostupné z: https://doi.org/10.1186/s40364-025-00799-7.

@article{2507108,
   author = {Kotulová, Jana and Baďurová, Klára and Chyra, Zuzana and Ševčíková, Sabina and Garbová, Nikola and Jelínek, Tomáš and Hájek, Roman and Hrdinka, Matouš},
   article_location = {LONDON},
   article_number = {July 2025},
   doi = {https://doi.org/10.1186/s40364-025-00799-7},
   keywords = {Multiple myeloma; Aberrant plasma cells; Hematooncology; Immunotarget; Immunotherapy; Surface proteome; Surfaceomics; Biomarker discovery},
   language = {eng},
   issn = {2050-7771},
   journal = {Biomarker Research},
   title = {Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential},
   url = {https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00799-7},
   volume = {13},
   year = {2025}
}

TY  - JOUR
ID  - 2507108
AU  - Kotulová, Jana - Baďurová, Klára - Chyra, Zuzana - Ševčíková, Sabina - Garbová, Nikola - Jelínek, Tomáš - Hájek, Roman - Hrdinka, Matouš
PY  - 2025
TI  - Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential
JF  - Biomarker Research
VL  - 13
IS  - July 2025
SP  - 1-26
EP  - 1-26
PB  - BMC
SN  - 20507771
KW  - Multiple myeloma
KW  - Aberrant plasma cells
KW  - Hematooncology
KW  - Immunotarget
KW  - Immunotherapy
KW  - Surface proteome
KW  - Surfaceomics
KW  - Biomarker discovery
UR  - https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00799-7
N2  - Multiple myeloma is a hematologic malignancy characterized by complex genetic and microenvironmental factors that drive disease progression and resistance to treatment. Despite advancements in therapies targeting established antigens, such as BCMA, CD38, SLAMF7, and GPRC5D, specific challenges persist, including antigen escape, treatment resistance, and off-tumor toxicity, highlighting the urgent need for novel therapeutic modalities. Recent advances in surface proteomics and integrative omics technologies have enabled the discovery of new surface antigens with the potential to address the challenges. By targeting antigens with higher tumor specificity and lower expression in healthy tissues, emerging immunotargets offer new avenues to minimize off-tumor toxicity and reduce the risk of relapse due to antigen loss or immune evasion. This review provides an overview of emerging immunotargets, summarizing their biological functions, roles in disease pathogenesis and immune evasion, and potential for therapeutic interventions. We focused on fifteen emerging targets currently in early clinical development or the preclinical phase, highlighting LILRB4, SEMA4A, ITGB7, CCR1, and CD70 as the most promising. These immunotargets demonstrate significant potential for next-generation immunotherapies, including antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Preclinical or early clinical studies show favorable safety profiles, high tumor specificity, and mechanisms to overcome immune resistance, collectively suggesting the potential for improved patient outcomes and reduced adverse effects. By presenting a comprehensive summary of these advances, this review underscores the translational potential of emerging immunotargets and provides insights to guide the development of innovative therapeutic approaches to improve outcomes for multiple myeloma patients.
ER  -

KOTULOVÁ, Jana; Klára BAĎUROVÁ; Zuzana CHYRA; Sabina ŠEVČÍKOVÁ; Nikola GARBOVÁ; Tomáš JELÍNEK; Roman HÁJEK a Matouš HRDINKA. Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. \textit{Biomarker Research}. LONDON: BMC, 2025, roč.~13, July 2025, s.~1-26. ISSN~2050-7771. Dostupné z: https://doi.org/10.1186/s40364-025-00799-7.

Přehled o publikaci